Identification	O
of	O
protective	O
B	B:C0282581
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
within	O
the	O
novel	O
malaria	O
vaccine	I:C0206255
candidate	O
P.	O
falciparum	I:C3849939
Schizont	I:C3849939
Egress	I:C3849939
Antigen	I:C3849939
-	I:C3849939
1	I:C3849939
Naturally	O
-	O
acquired	O
antibodies	O
to	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	O
in	O
children	O
.	O

Identification	O
of	O
protective	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
within	O
the	O
novel	O
malaria	B:C0206255
vaccine	I:C0206255
candidate	O
P.	O
falciparum	I:C3849939
Schizont	I:C3849939
Egress	I:C3849939
Antigen	I:C3849939
-	I:C3849939
1	I:C3849939
Naturally	O
-	O
acquired	O
antibodies	O
to	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	O
in	O
children	O
.	O

Identification	O
of	O
protective	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
within	O
the	O
novel	O
malaria	O
vaccine	I:C0206255
candidate	O
P.	B:C3849939
falciparum	I:C3849939
Schizont	I:C3849939
Egress	I:C3849939
Antigen	I:C3849939
-	I:C3849939
1	I:C3849939
Naturally	O
-	O
acquired	O
antibodies	O
to	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	O
in	O
children	O
.	O

Identification	O
of	O
protective	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
within	O
the	O
novel	O
malaria	O
vaccine	I:C0206255
candidate	O
P.	O
falciparum	I:C3849939
Schizont	I:C3849939
Egress	I:C3849939
Antigen	I:C3849939
-	I:C3849939
1	I:C3849939
Naturally	O
-	O
acquired	O
antibodies	B:C0003241
to	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	O
in	O
children	O
.	O

Identification	O
of	O
protective	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
within	O
the	O
novel	O
malaria	O
vaccine	I:C0206255
candidate	O
P.	O
falciparum	I:C3849939
Schizont	I:C3849939
Egress	I:C3849939
Antigen	I:C3849939
-	I:C3849939
1	I:C3849939
Naturally	O
-	O
acquired	O
antibodies	O
to	O
PfSEA	B:C3849939
-	I:C3849939
1A	I:C3849939
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	O
in	O
children	O
.	O

Identification	O
of	O
protective	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
within	O
the	O
novel	O
malaria	O
vaccine	I:C0206255
candidate	O
P.	O
falciparum	I:C3849939
Schizont	I:C3849939
Egress	I:C3849939
Antigen	I:C3849939
-	I:C3849939
1	I:C3849939
Naturally	O
-	O
acquired	O
antibodies	O
to	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	B:C0024530
in	O
children	O
.	O

Vaccination	B:C0042196
of	O
mice	O
with	O
PbSEA	O
-	I:C4040232
1A	I:C4040232
decreases	O
parasitemia	O
and	O
prolongs	O
survival	O
following	O
Plasmodium	O
berghei	I:C0032149
ANKA	I:C0032149
challenge	O
.	O

Vaccination	O
of	O
mice	B:C0025929
with	O
PbSEA	O
-	I:C4040232
1A	I:C4040232
decreases	O
parasitemia	O
and	O
prolongs	O
survival	O
following	O
Plasmodium	O
berghei	I:C0032149
ANKA	I:C0032149
challenge	O
.	O

Vaccination	O
of	O
mice	O
with	O
PbSEA	B:C4040232
-	I:C4040232
1A	I:C4040232
decreases	O
parasitemia	O
and	O
prolongs	O
survival	O
following	O
Plasmodium	O
berghei	I:C0032149
ANKA	I:C0032149
challenge	O
.	O

Vaccination	O
of	O
mice	O
with	O
PbSEA	O
-	I:C4040232
1A	I:C4040232
decreases	O
parasitemia	B:C0242723
and	O
prolongs	O
survival	O
following	O
Plasmodium	O
berghei	I:C0032149
ANKA	I:C0032149
challenge	O
.	O

Vaccination	O
of	O
mice	O
with	O
PbSEA	O
-	I:C4040232
1A	I:C4040232
decreases	O
parasitemia	O
and	O
prolongs	O
survival	O
following	O
Plasmodium	B:C0032149
berghei	I:C0032149
ANKA	I:C0032149
challenge	O
.	O

To	O
enhance	O
the	O
immunogenicity	B:C4277607
of	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
using	O
peptide	O
microarrays	O
probed	O
with	O
anti-sera	O
from	O
rPfSEA	O
-	I:C3849939
1A	I:C3849939
-	O
vaccinated	O
non-human	O
primates	O
.	O

To	O
enhance	O
the	O
immunogenicity	O
of	O
PfSEA	B:C3849939
-	I:C3849939
1A	I:C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
using	O
peptide	O
microarrays	O
probed	O
with	O
anti-sera	O
from	O
rPfSEA	O
-	I:C3849939
1A	I:C3849939
-	O
vaccinated	O
non-human	O
primates	O
.	O

To	O
enhance	O
the	O
immunogenicity	O
of	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
B	B:C0282581
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
using	O
peptide	O
microarrays	O
probed	O
with	O
anti-sera	O
from	O
rPfSEA	O
-	I:C3849939
1A	I:C3849939
-	O
vaccinated	O
non-human	O
primates	O
.	O

To	O
enhance	O
the	O
immunogenicity	O
of	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
using	O
peptide	B:C0030956
microarrays	O
probed	O
with	O
anti-sera	O
from	O
rPfSEA	O
-	I:C3849939
1A	I:C3849939
-	O
vaccinated	O
non-human	O
primates	O
.	O

To	O
enhance	O
the	O
immunogenicity	O
of	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
using	O
peptide	O
microarrays	O
probed	O
with	O
anti-sera	B:C0020960
from	O
rPfSEA	O
-	I:C3849939
1A	I:C3849939
-	O
vaccinated	O
non-human	O
primates	O
.	O

To	O
enhance	O
the	O
immunogenicity	O
of	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
using	O
peptide	O
microarrays	O
probed	O
with	O
anti-sera	O
from	O
rPfSEA	B:C3849939
-	I:C3849939
1A	I:C3849939
-	O
vaccinated	O
non-human	O
primates	O
.	O

To	O
enhance	O
the	O
immunogenicity	O
of	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
using	O
peptide	O
microarrays	O
probed	O
with	O
anti-sera	O
from	O
rPfSEA	O
-	I:C3849939
1A	I:C3849939
-	O
vaccinated	B:C1519885
non-human	O
primates	O
.	O

To	O
enhance	O
the	O
immunogenicity	O
of	O
PfSEA	O
-	I:C3849939
1A	I:C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
B	O
-	I:C0282581
cell	I:C0282581
epitopes	I:C0282581
using	O
peptide	O
microarrays	O
probed	O
with	O
anti-sera	O
from	O
rPfSEA	O
-	I:C3849939
1A	I:C3849939
-	O
vaccinated	O
non-human	O
primates	B:C0033147
.	O

We	O
evaluated	B:C0220825
the	O
relationship	O
between	O
epitope	O
-	O
specific	O
antibody	O
levels	O
and	O
protection	O
from	O
parasitemia	O
in	O
a	O
longitudinal	O
treatment	O
-	O
reinfection	O
cohort	O
in	O
Western	O
Kenya	I:C0022558
.	O

We	O
evaluated	O
the	O
relationship	O
between	O
epitope	B:C0003316
-	O
specific	O
antibody	O
levels	O
and	O
protection	O
from	O
parasitemia	O
in	O
a	O
longitudinal	O
treatment	O
-	O
reinfection	O
cohort	O
in	O
Western	O
Kenya	I:C0022558
.	O

We	O
evaluated	O
the	O
relationship	O
between	O
epitope	O
-	O
specific	O
antibody	B:C0003241
levels	O
and	O
protection	O
from	O
parasitemia	O
in	O
a	O
longitudinal	O
treatment	O
-	O
reinfection	O
cohort	O
in	O
Western	O
Kenya	I:C0022558
.	O

We	O
evaluated	O
the	O
relationship	O
between	O
epitope	O
-	O
specific	O
antibody	O
levels	O
and	O
protection	O
from	O
parasitemia	B:C0242723
in	O
a	O
longitudinal	O
treatment	O
-	O
reinfection	O
cohort	O
in	O
Western	O
Kenya	I:C0022558
.	O

We	O
evaluated	O
the	O
relationship	O
between	O
epitope	O
-	O
specific	O
antibody	O
levels	O
and	O
protection	O
from	O
parasitemia	O
in	O
a	O
longitudinal	O
treatment	B:C0087111
-	O
reinfection	O
cohort	O
in	O
Western	O
Kenya	I:C0022558
.	O

We	O
evaluated	O
the	O
relationship	O
between	O
epitope	O
-	O
specific	O
antibody	O
levels	O
and	O
protection	O
from	O
parasitemia	O
in	O
a	O
longitudinal	O
treatment	O
-	O
reinfection	O
cohort	B:C0599755
in	O
Western	O
Kenya	I:C0022558
.	O

We	O
evaluated	O
the	O
relationship	O
between	O
epitope	O
-	O
specific	O
antibody	O
levels	O
and	O
protection	O
from	O
parasitemia	O
in	O
a	O
longitudinal	O
treatment	O
-	O
reinfection	O
cohort	O
in	O
Western	B:C0022558
Kenya	I:C0022558
.	O

Antibodies	B:C0003241
to	O
three	O
epitopes	O
were	O
associated	O
with	O
16	O
-	O
17	O
%	O
decreased	O
parasitemia	O
over	O
an	O
18	O
-	O
week	O
high	O
transmission	O
season	O
.	O

Antibodies	O
to	O
three	O
epitopes	B:C0003316
were	O
associated	O
with	O
16	O
-	O
17	O
%	O
decreased	O
parasitemia	O
over	O
an	O
18	O
-	O
week	O
high	O
transmission	O
season	O
.	O

Antibodies	O
to	O
three	O
epitopes	O
were	O
associated	O
with	O
16	O
-	O
17	O
%	O
decreased	O
parasitemia	B:C0242723
over	O
an	O
18	O
-	O
week	O
high	O
transmission	O
season	O
.	O

We	O
are	O
currently	O
designing	O
immunogens	B:C0042213
to	O
enhance	O
antibody	O
responses	I:C0003261
to	O
these	O
three	O
epitopes	O
.	O

We	O
are	O
currently	O
designing	O
immunogens	O
to	O
enhance	O
antibody	B:C0003261
responses	I:C0003261
to	O
these	O
three	O
epitopes	O
.	O

We	O
are	O
currently	O
designing	O
immunogens	O
to	O
enhance	O
antibody	O
responses	I:C0003261
to	O
these	O
three	O
epitopes	B:C0003316
.	O

